Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322140 | 0.71 | CCND1 (0.37) | — | |
| SCHEMBL24322248 | 0.69 | — | — | |
| SCHEMBL18080342 | 0.64 | KDM4E (0.32) | — | |
| SCHEMBL4507655 | 0.64 | PDPK1 (0.34) | PDPK1 | |
| SCHEMBL2635489 | 0.61 | ERCC1 (0.50) | — | |
| SCHEMBL16654744 | 0.60 | ALDH1A1 (0.32) | — | |
| SCHEMBL12194764 | 0.60 | GPR35 (0.35) | — | |
| SCHEMBL23488021 | 0.59 | DAO (0.52) | — | |
| SCHEMBL19868119 | 0.59 | MEN1 (0.31) | — | |
| SCHEMBL16201663 | 0.59 | PDPK1 (0.33) | PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747261-A1 | AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | Accutar Biotechnology Inc. (US) | 2026-05-27 | — | — | EP | disclosed |
| US-12338248-B2 | Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors | ACCUTAR BIOTECHNOLOGY INC. (US) | 2025-06-24 | — | — | US | disclosed |
| US-20250084095-A1 | Aminopyrimidine Derivatives as Cyclin-Dependent Kinase Inhibitors | ACCUTAR BIOTECHNOLOGY INC. | 2025-03-13 | — | — | US | disclosed |
| WO-2025024388-A1 | AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2025-01-30 | — | — | WO | disclosed |
| WO-2024220866-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVES AS CYCLIN-DEPENDENT KINASE INHIBITORS | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | PRELUDE THERAPEUTICS, INCORPORATED | 2023-11-09 | — | — | US | disclosed |
| CN-116583283-A | CDK inhibitors and their use as pharmaceuticals | 普莱鲁德疗法有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | PRELUDE THERAPEUTICS INCORPORATED (US) | 2023-06-27 | — | — | US | disclosed |
| WO-2022061273-A1 | CDK INHIBITORS AND THEIR USE AS PHARMACEUTICALS | PRELUDE THERAPEUTICS, INCORPORATED (US) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338248-B2 | Aminopyrimidine derivatives as cyclin-dependent kinase inhibitors | CDK6, CDK2, CDK8 | PDPK1 78/4885 |
| US-20250084095-A1 | Aminopyrimidine Derivatives as Cyclin-Dependent Kinase Inhibitors | CDK6, CDK2, CDK8 | PDPK1 78/4885 |
| US-20230357265-A1 | CDK Inhibitors And Their Use As Pharmaceuticals | CDK6, CDK1, CDK3 | PDPK1 143/4885 |
| US-11685744-B2 | CDK inhibitors and their use as pharmaceuticals | CDK6, CDK1, CDK3 | PDPK1 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.